FDA Appeals Utah Ephedra Court Ruling, Defends Use Of Risk/Benefit Analysis

FDA's use of a risk/benefit analysis to show that ephedra presented an "unreasonable risk of illness or injury" was an appropriate means of supporting the ban of the ingredient in 2004, according to the agency